text.skipToContent text.skipToNavigation
Es konnten keine Ergebnisse gefunden werden.

How can we age more healthily in the future?

Beyond Science

Thanks in part to advances in molecular biology, the human population is living longer. This is obviously great news for us as individuals, but it does create problems and concerns for society. As lifespans increase, more people will develop diseases associated with ageing, such as dementia and cancer.
How can we not only live longer, but live healthily for longer?
Over the past 75 years that Eppendorf has been supporting biologists, our understanding of the way humans age has come a long way. We are now able to study how genetic changes within individual cells contribute to ageing and associated diseases. This is leading to more effective treatments, for when things go wrong.
This increased understanding has revealed the important role that the microbiome plays in ageing. The microbiome is composed of all microorganisms – bacteria, fungi, protozoa, and viruses – living in or on the human body. Studies have shown how the microbiome of our intestines changes dramatically during ageing, and that these changes are linked to human health and lifespan.
For example, the gut microbiome is thought to trigger changes in immunity and cognitive function, two key determinants in healthy ageing. Any decline in immune function increases the chance of infections and is thought to increase the chance of cancer. A decline in cognitive function is directly linked to dementia.
Ideally, to live a healthy life for longer we want to be free of disease. New treatments have helped us live longer with diseases such as cancer, however some of the treatments can have debilitating side-effects, reducing quality of life.
So, what are the challenges in finding cures for cancer and dementia in the next 75 years? In cancer, many successful therapies exist and thanks to researchers worldwide the breadth of therapies in continually expanding, for example with new immunotherapies such as CAR-T.
For dementia, the number of approvals for new treatments has been much lower. Alzheimer’s disease, the most common form of dementia, is still not fully understood, but with the advent of new molecular biology techniques, such as single-cell sequencing, our understanding of dementia and cancer should intensify.
As with the last 75 years, we will continue innovating to ensure molecular biologists have access to the most ground-breaking, reliable, and consistent products to give them the best chance of success in their research. And we look forward to continuing to reward this success through the Eppendorf Award for Young European Investigators .
For a quarter of a century, we’ve been supporting research into ageing and other areas of molecular biology through the Eppendorf Award for Young European Investigators in partnership with the journal Nature®. In 2018, Professor Andrea Ablasser was awarded the prize for her work showing how a mechanism involved in the immune response is also activated in ageing cells.